Overview and Scope
Anaplastic astrocytoma is a rare, malignant brain tumor that arises from astrocytes, the supportive cells in the nervous system. Anaplastic astrocytoma can cause neurological symptoms such as headaches, seizures, changes in behavior and motor deficits that are treated with a combination of surgery, radiation therapy and chemotherapies
Sizing and Forecast
The anaplastic astrocytoma market size has grown strongly in recent years. It will grow from $6.27 billion in 2023 to $6.62 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to growing adoption of targeted therapies, patient advocacy and awareness, clinical trial expansion, healthcare policy and funding, government initiatives.
The anaplastic astrocytoma market size is expected to see steady growth in the next few years. It will grow to $7.99 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The growth in the forecast period can be attributed to increasing research and development activities, growing demand for personalized medicine, growing investments, increasing awareness of the disease, increasing stress and depression. Major trends in the forecast period include advancements in neurosurgery, radiation therapy advancements, clinical trials and research, adoption of telemedicine and remote monitoring technologies, advancements in imaging, biotechnology and drug development.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/anaplastic-astrocytoma-global-market-report
Segmentation & Regional Insights
The anaplastic astrocytoma market covered in this report is segmented –
1) By Disease Type: Grade I; Grade II; Grade III; Grade IV
2) By Treatment Type: Surgery; Chemotherapy; Radiation
3) By Treatment Phase: Pre-Registration Phase; Clinical Trial Phase
4) By End-User: Hospitals And Clinics; Retail Pharmacy; Online Pharmacy
North America was the largest region in the anaplastic astrocytoma market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anaplastic astrocytoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12874&type=smp
Major Driver Impacting Market Growth
The growing incidence of primary malignant and non-malignant brain tumors is expected to propel the growth of the anaplastic astrocytoma market. Brain tumors are growths in the brain that can be classified as either cancerous (malignant) and invasive or non-cancerous (benign) and non-invasive, with varying degrees of aggressiveness and potential to spread. The anaplastic astrocytoma treatment removes the tumor and surrounding affected tissue while preserving brain function. For instance, in March 2023, according to the American Society of Clinical Oncology (ASCO), a US-based non-profit organization, approximately 24,810 adults in the United States are expected to receive a diagnosis of primary cancerous tumors originating in the brain and spinal cord, with 14,280 cases among men and 10,530 among women. Therefore, the growing incidence of primary malignant and non-malignant brain tumors will drive the growth of the anaplastic astrocytoma market going forward.
Key Industry Players
Major players in the anaplastic astrocytoma market are Pfizer Inc., Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Perrigo Company PLC, Ipsen SA, Genentech Inc., Cipla Limited, Novocure Ltd., Celon Laboratories Limited, Avid Bioservices Inc., EirGen Pharma Ltd., Monteris Medical Corporation, GLS Pharma Pvt. Ltd., Tocagen Inc., Pharma’s Almanac, Inovio Pharmaceuticals Inc., Isarna Therapeutics GmbH, Actiza Pharmaceutical Private Limited, Celldex Therapeutics Inc.
The anaplastic astrocytoma market report table of contents includes:
1. Executive Summary
2. Anaplastic Astrocytoma Market Characteristics
3. Anaplastic Astrocytoma Market Trends And Strategies
4. Anaplastic Astrocytoma Market – Macro Economic Scenario
5. Global Anaplastic Astrocytoma Market Size and Growth
.
.
.
26. South America Anaplastic Astrocytoma Market
27. Brazil Anaplastic Astrocytoma Market
28. Middle East Anaplastic Astrocytoma Market
29. Africa Anaplastic Astrocytoma Market
30. Anaplastic Astrocytoma Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Hoffmann-La Roche Ltd
- Merck & Co. Inc
- Novartis AG
- Amgen Inc
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
